Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2319 studies found for:    ovarian,cancer,treatment
Show Display Options
Rank Status Study
1 Active, not recruiting OVArian Cancer Non-Interventional Study - OVATAR
Condition: 1st Line Treatment and Diagnostic Serous or Endometrioid Ovarian, Peritoneal, Fallopian Tube Cancer, BRCAm+Occurence in Russia
Intervention:
2 Terminated Sexual Functioning After Primary Treatment of Ovarian Cancer
Conditions: Ovarian Cancer;   Sexual Dysfunction
Intervention: Behavioral: questionnaires
3 Completed Individualised Versus Conventional Medical Follow-up for Women After Primary Treatment for Ovarian Cancer.
Condition: Ovarian Cancer
Intervention: Behavioral: Individualised follow-up
4 Completed First Line Ovarian Cancer Treatment - Cohort Study
Condition: Epithelial Ovarian Cancer
Intervention: Drug: Bevacizumab
5 Completed Whole Body Diffusion MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Ovarian Cancer and Peritoneal Metastasis
Conditions: Ovarian Cancer;   Peritoneal Metastasis
Intervention: Procedure: intravenous contrast administration
6 Active, not recruiting Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Biological: filgrastim;   Biological: therapeutic autologous lymphocytes;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis
7 Active, not recruiting Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC
Condition: Ovarian Epithelial Cancer Recurrent
Intervention: Drug: Trabectedin and Pegylated Liposomal Doxorubicin
8 Terminated Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Biological: MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine;   Biological: tetanus toxoid helper peptide;   Drug: carboplatin;   Drug: paclitaxel;   Procedure: conventional surgery
9 Active, not recruiting SGI-110 in Combination With Carboplatin in Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: SGI-110 and carboplatin;   Drug: Treatment of Choice ( topotecan, pegylated liposomal doxorubicin, or paclitaxel)
10 Recruiting Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer
Conditions: Ovarian Cancer;   Endometrial Cancer
Intervention: Drug: everolimus and letrozole
11 Terminated Weekly Topotecan Therapy in Patients With Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: Topotecan
12 Recruiting Study of Predictive Factors of Chemoresistance in Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Procedure: Cancer treatment
13 Completed
Has Results
Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
Intervention: Drug: eribulin mesylate
14 Active, not recruiting Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)
Condition: Ovarian Cancer
Intervention: Drug: Yondelis®-Caelyx®
15 Recruiting The Efficacy of Involved-field Radiation Therapy for Residual or Locoregionally Recurrent Epithelial Ovarian Cancer After Definitive Treatment; Multi-institutional Clinical Trial
Condition: Ovarian Cancer (Epithelial)
Intervention: Radiation: involved-field radiation therapy
16 Completed Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Imatinib Mesylate;   Drug: Docetaxel
17 Completed
Has Results
A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
Conditions: Ovarian Sarcoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Akt Inhibitor MK2206;   Other: Laboratory Biomarker Analysis
18 Completed Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer
Conditions: Fallopian Tube Carcinoma;   Primary Peritoneal Carcinoma;   Recurrent Ovarian Carcinoma;   Stage III Ovarian Cancer;   Stage IV Ovarian Cancer
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Chemosensitization/Potentiation Therapy;   Drug: Docetaxel
19 Active, not recruiting TIL Therapy for Metastatic Ovarian Cancer
Condition: Metastatic Ovarian Cancer
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: TIL infusion;   Drug: Interleukin-2
20 Completed
Has Results
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Docetaxel;   Drug: Carboplatin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.